Veracyte

VCYT

Current ValuationThe current P/E ratio is 30.28, below the reasonable range, cheaper than 89.62% of the time in the past 1 years, and the industry ranks 49/605, the industry Median -1.87.

30.28xP/E
Stock price$43.12Earnings per share$1.42

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
021426384

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
BIIBUSBiogen
41.19x29.97%$34.37B
ALNYUSAlnylam Pharma
40.04x185.32%$31.02B
HALOUSHalozyme Therap
33.44x185.16%$13.83B
KRYSUSKrystal Biotech
38.81x7.46%$9.37B
VCYTUSVeracyte
30.28x35.02%$3.47B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.